title: Pharmaceutical approval update.
abstract: Vedolizumab (Entyvio) for ulcerative colitis and Crohn's disease; dalbavancin (Dalvance) for acute bacterial skin and skin structure infections; and antihemophilic factor, recombinant (Eloctate) for hemophilia A.
authors.forename: Marvin M
authors.initials: MM
authors.lastname: Goldenberg